Skip to main content
NCBI home page
Bulletin of the World Health Organization logoLink to Bulletin of the World Health Organization
. 2013 Sep 1;91(9):640–649. doi: 10.2471/BLT.12.116699

Cervical and female breast cancers in the Americas: current situation and opportunities for action

Cancer du col de l'utérus et cancer du sein sur le continent américain: situation actuelle et actions envisagées

Cáncer de cuello uterino y de mama en las Américas: situación actual y posibilidades de actuación

سرطان عنق الرحم وسرطان الثدي لدى النساء في الأميركتين : الوضع الراهن وفرص العمل

美洲子宫颈癌和乳腺癌:当前形势和采取行动的机会

Рак шейки матки и рак молочной железы у женщин в странах Америки: текущая ситуация и возможные действия

Silvana Luciani a,✉, Anna Cabanes a, Elisa Prieto-Lara a, Vilma Gawryszewski a
PMCID: PMC3790216  PMID: 24101780

Abstract

Objective

To understand better the current regional situation and public health response to cervical cancer and female breast cancer in the Americas.

Methods

Data on cervical cancer and female breast cancers in 33 countries, for the period from 2000 to the last year with available data, were extracted from the Pan American Health Organization (PAHO) Regional Mortality Database and analysed. Changes in mortality rates over the study period – in all countries except those with small populations and large fluctuations in time–series mortality data – were calculated using Poisson regression models. Information from the PAHO Country Capacity Survey on noncommunicable diseases was also analysed.

Findings

The Bahamas, Trinidad and Tobago and Uruguay showed relatively high rates of death from breast cancer, whereas the three highest rates of death from cervical cancer were observed in El Salvador, Nicaragua and Paraguay. Several countries – particularly Paraguay and Venezuela – have high rates of death from both types of cancer. Although mortality from cervical cancer has generally been decreasing in the Americas, decreases in mortality from breast cancer have only been observed in a few countries in the Region of the Americas. All but one of the 25 countries in the Americas included in the PAHO Country Capacity Survey reported having public health services for the screening and treatment of breast and cervical cancers.

Conclusion

Most countries in the Americas have the public health capacity needed to screen for – and treat – breast and cervical cancers and, therefore, the potential to reduce the burden posed by these cancers.

Introduction

Cancer represents 30% of the burden posed by noncommunicable diseases in the Region of the Americas of the World Health Organization (WHO), where the leading causes of death have shifted from infectious diseases to noncommunicable diseases.1 Changes in demographic, social, economic and environmental factors, as well as life course changes – for example, changes in reproductive patterns – have contributed greatly to this epidemiological shift.2

Breast and cervical cancers are generally considered to be the most important cancers among women in the Americas, as they are among women worldwide.3 Globally, breast cancer incidence and mortality have increased over the past 30 years, at estimated annual rates of 3.1% and 1.8%, respectively. Over the same period, cervical cancer incidence and mortality have also increased, at estimated annual rates of 0.6% and 0.46%, respectively.4 The corresponding trends in the Americas have generally matched these global trends.5

These increases have occurred even though effective, population-based interventions are available for the control of breast and cervical cancers and the prevention of unnecessary deaths from these cancers. For cervical cancer, these interventions include vaccination against human papillomavirus (HPV) infection, screening based on cervical cytology, visual inspection of the cervix after applying acetic acid and testing for HPV DNA, and effective treatment for precancerous lesions and invasive cancer.6 WHO currently recommends the routine administration of HPV vaccine to girls – as part of a country’s national immunization programme – if cervical cancer is a public health priority in the country and if such HPV vaccination is programmatically feasible and sustainable and appears to be cost-effective in the country.7 If it is systematically applied with high coverage and quality assurance, cytological screening can reduce cervical cancer mortality by more than 50%.8 For breast cancer, the disease can be detected in its early stages through breast self-examination, clinical breast examination and mammography screening. The effectiveness of these strategies has been found to vary according to the resources available and the needs of the population involved.9 In general, however, mammography screening has led to a substantial reduction – estimated to be about 15% – in breast cancer mortality.10

The implementation of technologies that could reduce mortality from breast and cervical cancers continues to be a challenge in resource-constrained settings such as those often seen in the Caribbean and Latin America. This is especially true where several public health priorities compete for attention.

To assess the burden posed by breast and cervical cancers in the Americas and to understand the associated public health response, we reviewed the information on these cancers provided to the Pan American Health Organization (PAHO) by the relevant National Institutes of Vital Statistics and health ministry officials. We reviewed the temporal trends in mortality from breast and cervical cancers since 2000 and the results of a recent survey on the capacity of national programmes to prevent, screen for and treat noncommunicable diseases.

Methods

We extracted data – on mortality from breast and cervical cancers – from the PAHO Regional Mortality Database, which includes deaths that have been registered in national vital registration systems and reported annually to PAHO.11 The quality of the data from each country was evaluated by verifying the integrity and consistency of the data and validating selected variables (i.e. sex, age and underlying cause of death). An algorithm to correct for under-registration and ill-defined causes was applied to the data from countries that show more than 10% under-registration, more than 10% of deaths with an ill-defined cause, or both.12 For each of the 33 countries in WHO’s Region of the Americas with complete data, we included data from 2000 to the last year with reported data. This period was used because it was when each of the countries coded mortality using the International statistical classification of diseases and related health problems, 10th revision (ICD-10).

For breast cancer mortality, we extracted all deaths attributed to “female malignant neoplasm of breast” (i.e. ICD-10 code C50). For cervical cancer mortality, we extracted all deaths attributed to “malignant neoplasm of cervix uteri” (C53), “malignant neoplasm of corpus uteri” (C54) or “malignant neoplasm of uterus, part unspecified” (C55). We applied a reallocation algorithm – as used in similar analyses on trends and geographical comparisons13 – to reassign a proportion of the deaths coded as C55 to “malignant neoplasm of cervix uteri” (C53), based on the age- and time-specific distributions of the deaths. Eleven countries coded small proportions of their deaths among females (≤ 25% of the total number among women aged 30 years or older) as C55. For these countries – Brazil, Chile, Colombia, Costa Rica, Cuba, Mexico, Nicaragua, Panama, Suriname, Trinidad and Tobago and Venezuela – we reallocated the C55 deaths (unspecified) to C53 (cervix) or C54 (uterus), using the same ratio seen between the deaths coded C53 and those coded C54 – in the same data set – for the same country, year and age group. However, for the 13 countries that coded higher proportions of their deaths among women aged 30 years or older as C55 – Argentina, Belize, Canada, Dominican Republic, Ecuador, El Salvador, Guatemala, Guyana, Paraguay, Peru, Puerto Rico, Uruguay and the United States of America – the deaths coded C55 for each year were reallocated to C53 or C54 using the same ratio seen between the deaths coded C53 and those coded C54 in an appropriate reference country in the same year. The reference countries used were Chile for the data from Argentina, Ecuador, Paraguay, Peru and Uruguay; Mexico for the data from Belize, Canada, the Dominican Republic, El Salvador, Guatemala, Puerto Rico and the United States; and Trinidad and Tobago for the data from Guyana. The selection of the reference countries was based on the high quality of their vital statistics data, the consistently low proportions of their deaths that were coded C55, and their geographical, demographic and socioeconomic characteristics.

Age-standardized mortality rates were calculated using the world standard population.14 For those countries that did not have small populations and did not show large fluctuations in the time–series mortality data, annual changes in mortality rates were evaluated using Poisson regression models.

Information on the capacity of national public health programmes to deal with breast and cervical cancers was extracted – for the 25 countries in the Americas that provided the relevant data – from the PAHO Country Capacity Survey on noncommunicable diseases (S. Luciani, unpublished observations, 2013). This survey, which was conducted in April 2012, was based on a structured questionnaire which, for each targeted country, was sent to the health ministry staff members responsible for the national programme against noncommunicable diseases.

Results

In 2007, approximately 107 000 registered deaths in the Americas were attributed to female breast cancer (n = 82 370) or cervical cancer (n = 24 526),1 although another 12 240 deaths were reported as being from “cancer of the uterus, part unspecified” and some of these may have been from cervical cancer.

Breast cancer is the most common cause of cancer-related deaths among women in most countries in the Americas (Table 1). In Belize, El Salvador, Ecuador, Nicaragua, Paraguay and Peru, however, cervical cancer is the most common cause of cancer deaths among women (Table 2).

Table 1. Mortality from female breast cancer in the Region of the Americas, 2000–2009.

Country or territory Populationa (thousands) GNIa (US$ per capita) Mortality from female breast cancer
 APCd (95% CI)
Deaths in 2000 ASMRb in 2000 Latest yearc Deaths in latest yearc ASMRb in latest yearc
North America
Canada 34 675 39 830 4857 18.1 2007 5066 15.6 −2.25 (−2.67 to −1.83)
United States of America 315 791 48 890 41 875 17.3 2007 40 600 14.8 −2.19 (−2.34 to −2.04)
Mexico and Central America
Belize 324 6070 5 7.7 2008 12 12.8 3.58 (−5.55 to 13.6)
Costa Rica 4794 11 950 183 10.6 2009 242 11.4 0.52 (−0.94 to 1.99)
El Salvador 6264 6690 144 5.6 2008 233 7.7 3.52 (1.61 to 5.46)
Guatemala 15 138 4800 177 4.2 2008 220 4.7 ND
Mexico 116 147 15 120 3433 8.7 2009 4803 9.0 0.39 (0.05 to 0.73)
Nicaragua 5955 2840 153 9.7 2009 227 11.1 −0.05 (−1.69 to 1.61)
Panama 3625 14 740 169 13.3 2009 207 12.1 −0.16 (−1.81 to 1.51)
South America
Andean Area
    Colombia 47 551 9640 1909 12.0 2008 2827 13.2 0.80 (0.27 to 1.32)
    Ecuador 14 865 8310 344 7.2 2009 593 9.2 1.87 (0.83 to 2.92)
    Peru 29 734 10 160 1187 12.0 2007 1261 10.2 −0.46 (−1.35 to 0.44)
    Venezuela 29 891 12 620 1344 14.3 2007 1817 15.1 0.82 (0.05 to 1.59)
Brazil 198 361 11 500 11 354 14.5 2009 15 769 14.9 0.09 (−0.10 to 0.27)
Southern Cone
    Argentina 41 119 17 250 5026 19.9 2009 5378 17.8 −1.21 (−1.51 to −0.92)
    Chile 17 423 16 160 1027 11.7 2008 1184 10.4 −1.40 (−2.15 to −0.64)
    Paraguay 6683 5310 310 16.2 2009 474 18.5 1.34 (0.25 to 2.43)
    Uruguay 3391 14 740 693 25.3 2004 659 22.0 ND
Caribbean
“Latin” Caribbean
    Cuba 11 249 NA 1118 14.3 2009 1415 15.4 1.16 (0.44 to 1.89)
    Dominican Republic 10 183 9490 426 13.1 2004 503 13.4 ND
    Puerto Rico 3743 16 560 341 12.3 2007 416 12.3 −0.56 (−2.09 to 0.99)
“English” Caribbean
    Antigua and Barbuda 89 15 670 12 28.9 2009 10 21.4 ND
    Aruba 108 NA 7 11.4 2009 13 15.5 ND
    Bahamas 351 29 850 28 20.5 2008 44 22.8 ND
    Bermuda – – 13 19.7 2008 9 12.9 ND
    Dominica 73 12 460 6 20.6 2009 8 16.5 ND
    Grenada 109 10 530 4 7.3 2009 11 16.1 ND
    Guyana 758 3460 78 25.9 2006 35 9.8 ND
    Saint Kitts and Nevis 51 14 490 8 30.0 2008 6 22.2 ND
    Saint Vincent and the Grenadines 104 10 560 7 14.5 2008 16 28.6 ND
    Suriname 534 NA 19 8.6 2007 24 10.0 −1.76 (−7.71 to 4.57)
    Trinidad and Tobago 1351 24 940 127 19.2 2007 163 21.6 4.57 (1.80 to 7.42)
    United States Virgin Islands 105 NA 17 23.1 2007 10 11.4 ND
Open in a new tab

APC, annual percentage change; ASMR, age-standardized mortality rate; CI, confidence interval; GNI, gross national income; NA, not available; ND, not determined; US$, United States dollar.

a Data for the year 2012, from the records of the Pan American Health Organization.15

b Deaths per 100 000 females.

c Latest year for which relevant data on mortality from breast cancer were available.

d In ASMR between 2000 and the latest year for which data were available.

Table 2. Mortality from cervical cancer in the Region of the Americas, 2000–2009.

Country or territory Mortality from cervical cancer
 APCc (95% CI)
Deaths in 2000 ASMRa in 2000 Latest yearb Deaths in latest yearb ASMRa in latest yearb
Northern America
Canada 703 2.7 2007 730 2.4 −2.21 (−3.31 to −1.09)
United States of America 7460 3.3 2007 7786 3.1 −1.18 (−1.52 to −0.83)
Mexico and Central America
Belize 17 23.2 2008 16 15.5 −7.43 (−12.89 to −1.63)
Costa Rica 151 9.1 2009 117 5.1 −6.65 (−8.44 to −4.82)
El Salvador 611 23.6 2008 566 17.9 −3.01 (−4.01 to −2.0)
Mexico 4944 12.3 2009 4326 8.0 −4.86 (−5.17 to −4.56)
Nicaragua 380 24.1 2009 421 19.4 −3.73 (−4.76 to −2.68)
Panama 153 12.0 2009 147 8.5 −5.43 (−7.01 to −3.83)
South America
Andean Area
    Colombia 2416 14.7 2008 2609 12.0 −3.05 (−3.54 to −2.56)
    Ecuador 694 13.9 2009 885 13.3 −0.86 (−1.63 to −0.08)
    Peru 2117 20.9 2007 2031 16.3 −1.15 (−1.85 to −0.44)
    Venezuela 1548 15.9 2007 1856 14.9 −1.31 (−2.02 to −0.06)
Brazil 7965 10.1 2009 8920 8.4 −2.2 (−2.43 to −1.97)
Southern Cone
    Argentina 1861 8.4 2009 1955 7.6 −0.99 (−1.48 to −0.49)
    Chile 771 8.9 2008 685 6.1 −4.02 (−4.91 to −3.12)
    Paraguay 549 28.6 2009 537 20.5 −3.49 (−4.35 to −2.63)
Caribbean
Cuba 531 7.2 2009 593 7.0 −0.16 (−1.18 to 0.87)
Guyana 72 22.8 2006 44 12.7 −4.88 (−9.77 to 0.27)
Puerto Rico 94 3.5 2007 106 3.4 −1.79 (−4.65 to 1.16)
Suriname 26 12.6 2007 21 8.3 −4.77 (−10.37 to 1.17)
Trinidad and Tobago 89 13.6 2007 95 12.9 −1.59 (−4.80 to 1.73)
Open in a new tab

APC, annual percentage change; ASMR, age-standardized mortality rate; CI, confidence interval.

a Deaths per 100 000 females.

b Latest year for which relevant data on mortality from cervical cancer were available.

c In ASMR between 2000 and the latest year for which data were available.

Within the Americas, mortality from female breast cancer is relatively high in the countries of the Southern Cone and the “English” Caribbean. According to the most recent data, the age-standardized annual rate of death from breast cancer is 22.8 deaths per 100 000 females in the Bahamas, 21.6 deaths per 100 000 females in Trinidad and Tobago and 22.0 deaths per 100 000 females in Uruguay (Table 1). The lowest rates of death from female breast cancer in recent years were observed in El Salvador and Guatemala, whereas Brazil, Canada and the United States showed intermediate values (Table 1).

Recent data on cervical cancer mortality (Table 2) show relatively high annual rates in El Salvador, Nicaragua and Paraguay – with 17.9, 19.4 and 20.5 deaths per 100 000 females, respectively – and relatively low rates in Canada, Puerto Rico and the United States – with 2.4, 3.4 and 3.1 deaths per 100 000 females, respectively.

In some countries the rate of death from female breast cancer is substantially greater than that from cervical cancer. One example is Brazil, which in 2009 recorded rates of 14.9 and 8.4 deaths per 100 000 females, breast and cervical cancer, respectively. In other countries the two types of cancer cause similar mortality. This applies to Mexico, which in 2009 recorded 9.0 deaths from breast cancer and 8.0 deaths from cervical cancer per 100 000 females. And there are still other countries where the rate of death from female breast cancer is much lower than that from cervical cancer. In Nicaragua in 2009, for example, the rate of death from female breast cancer was almost half as high as the rate of death from cervical cancer – 11.1 and 19.4 deaths per 100 000 females, respectively.

Two of the countries that we investigated had relatively high rates of death from both female breast cancer and cervical cancer. One was Paraguay, with 18.5 deaths from breast cancer and 20.5 deaths from cervical cancer per 100 000 females in 2009; the other was Venezuela, with corresponding rates of 15.1 and 14.9 deaths per 100 000 in 2007 for breast and cervical cancer, respectively.

Of the 19 countries included in the analysis of temporal trends in mortality from breast and cervical cancers, four showed substantial declines in breast cancer mortality since 2000, with annual percentage changes ranging from –1.21% (95% confidence interval, CI: –1.51 to –0.92) in Argentina to –2.25% (95% CI: –2.67 to –1.83) in Canada (Table 1). Another eight countries showed substantial increases in breast cancer mortality since 2000, with annual percentage changes as high as 3.52% (95% CI: 1.61 to 5.46) in El Salvador and 4.57% (95% CI: 1.80 to 7.42) in Trinidad and Tobago (Table 1).

Since 2000, mortality from cervical cancer has been decreasing in almost all of the countries included in the analysis of temporal trends, with the greatest annual percentage changes observed in Costa Rica (–6.65%; 95% CI: –8.44 to –4.82) and Panama (–5.43%; 95% CI: –7.01 to –3.83) (Table 2)

The trends for breast cancer mortality in relation to cervical cancer mortality followed three patterns: countries such as Brazil have maintained a higher rate of breast cancer mortality, whereas other countries, such as Mexico, have seen declines in cervical cancer mortality but increases in breast cancer mortality. Still others, such as Nicaragua, have maintained a higher rate of cervical cancer mortality (Fig. 1, Fig. 2 and Fig. 3).

Fig. 1.

Temporal trends in mortality from cervical and female breast cancers, Brazil, 2000–2009

ASMR, age-standardized mortality rate.

Fig. 1

Open in a new tab

Fig. 2.

Temporal trends in mortality from cervical and female breast cancers, Mexico, 2000–2009

ASMR, age-standardized mortality rate.

Fig. 2

Open in a new tab

Fig. 3.

Temporal trends in mortality from cervical and female breast cancers, Nicaragua, 2000–2009

ASMR, age-standardized mortality rate.

Fig. 3

Open in a new tab

National policies and plans for the prevention and treatment of cancer exist in most of the countries we investigated and public health screening services for breast and cervical cancer are reported to be in place in 24 of the 25 countries that provided data for the PAHO Country Capacity Survey (Table 3). Cervical cancer screening is predominantly based on cytological testing in 24 countries, although 10 countries reported that they also offered testing for HPV DNA and 11 countries reported that they offered screening by visual inspection of the cervix after application of acetic acid. Although 24 countries reported that they offered free cytological screening for cervical cancer, only eight reported having free mammography-based screening services for breast cancer.

Table 3. Capacity to screen for, prevent and treat breast and cervical cancers in Latin America and the Caribbean, 2012.

Parameter South Americaa Mexico and Central Americab “Latin” Caribbeanc “English” Caribbeand
Cancer policy
Cancer policy All countries except Paraguay Costa Rica and Guatemala All countries Barbados, Dominica, Jamaica, Suriname, Trinidad and Tobago
Action plan for cancer All countries except Ecuador All countries except Belize All countries All countries and territories except Antigua and Barbuda, Saint Kitts and Nevis, Saint Vincent and the Grenadines
Cervical cancer screening
Cytology
    Available All countries All countries All countries All countries and territories
    Free All countries except Bolivia and Peru All countries Cuba and Dominican Republic All countries and territories except Saint Vincent and the Grenadines and Suriname
HPV DNA test Argentina, Brazil, Chile, Colombia, Ecuador, Paraguay, Uruguay and Venezuela Mexico None Bahamas
Visual inspection of cervix with acetic acid Bolivia, Colombia, Paraguay and Peru El Salvador, Guatemala and Nicaragua Cuba and Puerto Rica Guyana and Suriname
Breast cancer screening
Clinical breast examination All countries except Bolivia All countries All countries All countries and territories
Mammography
    Available All countries except Bolivia All countries except Guatemala Cuba and Puerto Rico All countries and territories except Grenada
    Free All countries that have it available except Argentina, Paraguay and Peru Costa Rica, Mexico and Nicaragua Cuba Barbados, Guyana, Jamaica, Saint Lucia and Trinidad and Tobago
Cancer treatment
Chemotherapye
    Available All countries All countries except Belize All countries All countries and territories except Saint Kitts and Nevis
    Free All countries except Bolivia Costa Rica, Mexico and Nicaragua Cuba Antigua and Barbuda, Barbados, Grenada, Guyana, Jamaica and Trinidad and Tobago
Radiation therapy
    Available All countries All countries except Belize All countries Bahamas, Barbados, Guyana, Jamaica, Suriname and Trinidad and Tobago
    Free All countries except Bolivia and Peru Costa Rica, Mexico and Nicaragua Cuba Barbados, Guyana, Jamaica and Trinidad and Tobago
Tamoxifen
    Available All countries except Paraguay All countries except El Salvador and Guatemala All countries All countries and territories except Saint Kitts and Nevis and Grenada
    Free Brazil, Chile, Ecuador and Venezuela Costa Rica and Nicaragua Cuba Antigua and Barbuda, Barbados, Dominica, Guyana, Jamaica and Trinidad and Tobago
Oral morphine
    Available All countries except Paraguay Belize, Costa Rica and Panama Cuba and Puerto Rico All countries and territories except Guyana and Saint Kitts and Nevis
    Free Brazil, Chile and Venezuela Belize and, Costa Rica Cuba Antigua and Barbuda, Barbados, Dominica, Grenada, Jamaica and Trinidad and Tobago
Open in a new tab

DNA, deoxyribonucleic acid; HPV, human papillomavirus.

a Information available for Argentina, Bolivia, Brazil, Chile, Colombia, Ecuador, Paraguay, Peru, Uruguay and Venezuela.

b Information available for Belize, Costa Rica, El Salvador, Guatemala, Honduras, Mexico, Nicaragua and Panama.

c Information available for Cuba, Dominican Republic and Puerto Rico.

d Information available for Antigua and Barbuda, Bahamas, Barbados, Dominica, Grenada, Guyana, Jamaica, Saint Kitts and Nevis, Saint Lucia, Saint Vincent and the Grenadines, Suriname, Trinidad and Tobago.

e Chemotherapy refers to the list of cytotoxic medicines contained in the WHO Model List of Essential Medicines (17th list, March 2011), accessible at: http://whqlibdoc.who.int/hq/2011/a95053_eng.pdf

For cancer treatment, almost all of the 25 countries that provided data for the PAHO Country Capacity Survey reported the availability of chemotherapy, but eight countries, mainly in the Caribbean, reported that they had no radiotherapy available. In many countries, patients have to contribute financially to the costs of chemotherapy and – where available – radiotherapy. Although most of the countries reported having tamoxifen widely available, patients – even the poorest – were also charged for this drug. Most of the countries included in the survey reported having oral morphine available for palliative care. However, such medication was reportedly unavailable in seven of the countries, most of them in Central America.

Discussion

This brief descriptive analysis calls attention to the significant problem of breast and cervical cancers in all countries and territories of the Region of the Americas, and to the capacity that is available for the early detection and treatment of such cancers in the Region. It highlights the inequities represented by cervical cancer, which disproportionately affects women in the poorer countries, especially those with gross national incomes of less than 10 000 United States dollars per capita (Table 1 and Table 2). It also highlights the growing burden from breast cancer in several countries in Latin America and the Caribbean and the “double burden” of high mortality from both breast and cervical cancer faced by some of these countries.

Most of deaths from cervical cancer reported throughout the Americas were registered in Latin America or the Caribbean. This north–south divide can be seen in Appendix A (available at: http://www.paho.org/cancer/Appendix-A). The numbers of deaths from breast cancer in North America were, however, similar to the combined numbers for Latin America and the Caribbean (Appendix A). Within the countries and territories of Latin America and the Caribbean, the highest mortality rates from female breast cancer – seen in the countries of the Southern Cone – have been up to five times higher than the corresponding lowest rates – seen in Central America. Conversely, the highest rates of mortality from cervical cancer have been seen in Central America and have been up to three times higher than those recorded in the Southern Cone. These differences may be attributable to the level of socioeconomic development in each country and/or to geographical differences in access to screening, early diagnosis and treatment services.16–19

This review validates several recent reports on mortality from breast and cervical cancers in the Americas.5,16–25 In general, it has revealed temporal trends similar to those reported worldwide.4 However, several countries in the Americas have achieved important reductions in mortality from breast or cervical cancers over the last decade: Canada and the United States have achieved such reductions for breast cancer, whereas Chile, Costa Rica and Mexico have observed such reductions for cervical cancer. The relatively low annual numbers of deaths from both breast cancer and cervical cancer reported by the countries and territories of the Caribbean are potentially misleading, since they are reflections of small national populations and not of low mortality rates. The lack of radiotherapy in several of the small island nations of the Caribbean is a problem that needs to be resolved.

Progress in the development and implementation of policies, programmes and interventions against breast and cervical cancers have been seen in the Region of the Americas for several years.26–28 Since all the countries in the Region now have screening programmes for cervical cancer,25 several Latin American countries are now offering testing for HPV DNA in their national cervical cancer programmes26 and several report capacity for mammography screening.29 Effective screening for cervical cancer may partly explain recent declines in rates of mortality from such cancer. The continuing rise in mortality from breast cancer in several countries and territories of Latin America and the Caribbean is discouraging and probably a reflection of poor general access to health care and to a severe shortage of the resources needed to screen for such cancer.

According to some reports, in several countries in the Americas that have the capacity for screening and early detection, the main focus is still on treatment, with late-stage diagnosis and poor outcomes commonly observed.18 Such a focus can lead to low coverages in screening for both cervical cancer26 and breast cancer. In some countries mammography is limited to highly educated women or is unavailable to women who lack health insurance.30

The present analysis was based on deaths registered by national authorities and reported to PAHO, with corrections to account for any under-registration of mortality. Our mortality data differ from those presented in GLOBOCAN 2008,3 as they remain largely unchanged by estimation and prediction. There are, however, some limitations in using the mortality data reported to PAHO. First, PAHO has no mortality data from Bolivia, Haiti, Honduras or Jamaica, so these countries could not be included in this regional analysis. Second, PAHO only had incomplete mortality data for Anguilla, the British Virgin Islands, the Cayman Islands, Dominica, the Dominican Republic, French Guiana, Guadeloupe, Guatemala, Martinique, the former Netherlands Antilles, Saint Lucia, Turks and Caicos and Uruguay – although the data that were available for the Dominican Republic, Guatemala and Uruguay were sufficient for these three countries to be included in our analysis. As no subnational data for most countries in the Americas were available in the PAHO mortality database, no within-country comparisons of mortality rates were made. There is a general need to strengthen the vital statistics systems in most countries of Latin America and the Caribbean – to permit improvements in the quality, completeness and timeliness of the data collected on mortality – and to create or strengthen population-based cancer registries.

To enable comparisons between countries and take into consideration the substantial number of deaths recorded as being from “malignant neoplasm of uterus, parts unspecified” (i.e. ICD-10 code C55) we reassigned deaths attributed to C55 to a more specific cause of either cancer of the cervix or cancer of the uterus. This reassignment was possible for most of the countries included in our analyses; the exceptions were Caribbean countries and territories that reported small numbers of deaths from cervical cancer. As countries in the Region of the Americas do not apply a reallocation algorithm in reporting their national mortalities from cervical cancer, the data presented in this paper may vary from those presented in national reports by ministries of health. By applying the reallocation procedure, we tried to accommodate the underestimation of deaths from cervical cancer, adjust for any temporal improvements in data coding over the study period and improve the validity of any between-country comparisons. There were, however, limitations in using the procedure, particularly because there is no ideal reference population.

Low- and middle-income countries in the Americas are clearly making efforts – via screening and treatment programmes – to address the problems posed by breast and cervical cancers. In addition, by 2012 nine countries in the Region of the Americas – Argentina, Canada, Guyana, Mexico, Panama, Peru, Suriname, Trinidad and Tobago, and the United States – had introduced HPV vaccination into their national immunization programmes.28 The Region’s political and technical commitment to the control and treatment of cancer in general and cervical cancer in particular is demonstrated by the endorsement, by the Regions’ ministers of health, of a Regional Strategy and Plan of Action for Cervical Cancer Prevention and Control.31 Several countries in the Region have already implemented large-scale interventions that have demonstrated the feasibility and effectiveness of comprehensive programmes against cervical cancer and breast cancer.32,33 A network of South American cancer institutes known as RINC/UNASUR (for Red de Institutos Nacionales de Cáncer/Unión de Naciones Suramericanas) collaborates to strengthen programmes against breast and cervical cancer.34

The inequities represented by morbidity and mortality from breast and cervical cancers need to be reduced, perhaps by the use of existing health platforms, such as maternal and reproductive health programmes, to combat these women’s cancers.35,36 Although most countries in the Americas have some public health capacity for the control of breast and cervical cancers, the burden posed by these cancers could be reduced further by strengthening such capacity.

Competing interests:

None declared.

References

  • 1.Resolution CSP28.R13. Strategy for the Prevention and Control of Noncommunicable diseases. In: 28th Pan American Sanitary Conference, Washington, 17–21 September 2012: resolutions. Washington: PAHO; 2013. Available from: http://new.paho.org/hq/index.php?option=com_content&view=article&id=7022&Itemid=39541&lang=en [accessed 19 June 2013].
  • 2.Health in the Americas: regional overview and country profiles Washington: Pan American Health Organization; 2012. [Google Scholar]
  • 3.Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. GLOBOCAN 2008 v 2.0, cancer incidence and mortality worldwide Lyon: International Agency for Research on Cancer; 2010. [Google Scholar]
  • 4.Forouzanfar MH, Foreman KJ, Delossantos AM, Lozano R, Lopez AD, Murray CJL, et al. Breast and cervical cancer in 187 countries between 1980 and 2010: a systematic analysis. Lancet. 2011;378:1461–84. doi: 10.1016/S0140-6736(11)61351-2. [DOI] [PubMed] [Google Scholar]
  • 5.The challenge ahead: progress and setbacks in breast and cervical cancer: regional overviews Seattle: Institute for Health Metrics and Evaluation; 2011. [Google Scholar]
  • 6.Comprehensive cervical cancer control: a guide to essential practice Geneva: World Health Organization; 2006. [PubMed] [Google Scholar]
  • 7.World Health Organization Human papillomavirus vaccines. WHO position paper. Wkly Epidemiol Rec. 2009;84:118–31. [PubMed] [Google Scholar]
  • 8.Kitchener HC, Castle PE, Cox JT. Achievements and limitations of cervical cytology screening. Vaccine. 2006;24(Suppl 3):63–70. doi: 10.1016/j.vaccine.2006.05.113. [DOI] [PubMed] [Google Scholar]
  • 9.Anderson BO, Yip CH, Smith RA, Shyyan R, Sener SF, Eniu A, et al. Guideline implementation for breast healthcare in low-income and middle-income countries: overview of the Breast Health Global Initiative Global Summit 2007. Cancer. 2008;113(Suppl):2221–43. doi: 10.1002/cncr.23844. [DOI] [PubMed] [Google Scholar]
  • 10.Gøtzsche PC, Nielsen M. Screening for breast cancer with mammography. Cochrane Database Syst Rev. 2011;(1):CD001877. doi: 10.1002/14651858.CD001877.pub4. [DOI] [PubMed] [Google Scholar]
  • 11.Pan American Health Organization [Internet]. Regional Health Observatory, regional mortality database. Washington: Pan American Health Organization; 2011. Available from: http://new.paho.org/hq/index.php?option=com_content&task=view&id=4456&Itemid=2392 [accessed 19 June 2013].
  • 12.Pan American Health Organization On the estimation of mortality rates for countries of the Americas. Epidemiol Bull. 2003;24:1–5. [PubMed] [Google Scholar]
  • 13.Loos AH, Bray F, McCarron P, Weiderpass E, Hakama M, Parkin DM. Sheep and goats: separating cervix and corpus uteri from imprecisely coded uterine cancer deaths, for studies of geographical and temporal variations in mortality. Eur J Cancer. 2004;40:2794–803. doi: 10.1016/j.ejca.2004.09.007. [DOI] [PubMed] [Google Scholar]
  • 14.World population prospects: the 2010 revision New York: United Nations; 2011. [Google Scholar]
  • 15.Basic health indicators. Washington: Pan American Health Organization; 2012. [Google Scholar]
  • 16.Bray F, Jemal A, Grey N, Ferlay J, Forman D. Global cancer transitions according to the Human Development Index (2008–2030): a population-based study. Lancet Oncol. 2012;13:790–801. doi: 10.1016/S1470-2045(12)70211-5. [DOI] [PubMed] [Google Scholar]
  • 17.Lozano-Ascencio R, Gómez-Dantés H, Lewis S, Torres-Sánchez L, López-Carrillo L. Tendencias del cáncer de mama en América Latina y el Caribe. Salud Publica Mex. 2009;51(Suppl 2):s147–56. doi: 10.1590/S0036-36342009000800004. [DOI] [PubMed] [Google Scholar]
  • 18.Justo N, Wilking N, Jönsson B, Luciani S, Cazap E. A review of breast cancer care and outcomes in Latin America. Oncologist. 2013;18:248–56. doi: 10.1634/theoncologist.2012-0373. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Robles SC, Galanis E. Breast cancer in Latin America and the Caribbean. Rev Panam Salud Publica. 2002;11:178–85. doi: 10.1590/S1020-49892002000300007. [DOI] [PubMed] [Google Scholar]
  • 20.Anderson BO, Cazap E. Breast Health Global Initiative (BHGI) outline for program development in Latin America. Salud Publica Mex. 2009;51(Suppl 2):s309–15. doi: 10.1590/S0036-36342009000800022. [DOI] [PubMed] [Google Scholar]
  • 21.Lee BL, Liedke PER, Barrios CH, Simon SD, Finkelstein DM, Goss PE. Breast cancer in Brazil: present status and future goals. Lancet Oncol. 2012;13:e95–102. doi: 10.1016/S1470-2045(11)70323-0. [DOI] [PubMed] [Google Scholar]
  • 22.Freitas-Junior R, Gonzaga CM, Freitas NM, Martins E, Dardes RdeC. Disparities in female breast cancer mortality rates in Brazil between 1980 and 2009. Clinics (Sao Paulo) 2012;67:731–7. doi: 10.6061/clinics/2012(07)05. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Pedraza AM, Pollán M, Pastor-Barriuso R, Cabanes A. Disparities in breast cancer mortality trends in a middle income country. Breast Cancer Res Treat. 2012;134:1199–207. doi: 10.1007/s10549-012-2026-4. [DOI] [PubMed] [Google Scholar]
  • 24.Arbyn M, Castellsagué X, de Sanjosé S, Bruni L, Saraiya M, Bray F, et al. Worldwide burden of cervical cancer in 2008. Ann Oncol. 2011;22:2675–86. doi: 10.1093/annonc/mdr015. [DOI] [PubMed] [Google Scholar]
  • 25.Arrossi S, Sankaranarayanan R, Parkin DM. Incidence and mortality of cervical cancer in Latin America. Salud Publica Mex. 2003;45(Suppl 3):S306–14. doi: 10.1590/S0036-36342003000900004. [DOI] [PubMed] [Google Scholar]
  • 26.Cervical cancer prevention and control programs: a rapid assessment in 12 countries of Latin America Washington: Pan American Health Organization; 2010. Available from: http://new.paho.org/hq/index.php?option=com_content&view=category&layout=blog&id=3595&Itemid=3637&lang=en [accessed 19 June 2013].
  • 27.Luciani S. Cervical cancer burden and screening programs in Latin America and the Caribbean Madrid: Fundación para el Progreso de la Educación y la Salud; 2012. [Google Scholar]
  • 28.Munoz N. Progress in HPV vaccine introduction in Latin America. Madrid: Fundación para el Progreso de la Educación y la Salud; 2012. [Google Scholar]
  • 29.Cazap E, Buzaid AC, Garbino C, de la Garza J, Orlandi FJ, Schwartsmann G, et al. Latin American and Caribbean Society of Medical Oncology Breast cancer in Latin America: results of the Latin American and Caribbean Society of Medical Oncology/Breast Cancer Research Foundation expert survey. Cancer. 2008;113(Suppl):2359–65. doi: 10.1002/cncr.23834. [DOI] [PubMed] [Google Scholar]
  • 30.Reyes-Ortiz CA, Freeman JL, Peláez M, Markides KS, Goodwin JS. Mammography use among older women of seven Latin American and Caribbean cities. Prev Med. 2006;42:375–80. doi: 10.1016/j.ypmed.2006.02.005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Luciani S, Andrus JK. A Pan American Health Organization strategy for cervical cancer prevention and control in Latin America and the Caribbean. Reprod Health Matters. 2008;16:59–66. doi: 10.1016/S0968-8080(08)32405-7. [DOI] [PubMed] [Google Scholar]
  • 32.González-Robledo LM, González-Robledo MC, Nigenda G, López-Carrillo L.Acciones gubernamentales para la detección temprana del cáncer de mama en América Latina: retos a futuro. Salud Publica Mex 201052533–43.Spanish 10.1590/S0036-36342010000600009 [DOI] [PubMed] [Google Scholar]
  • 33.Almonte M, Murillo R, Sánchez GI, Jerónimo J, Salmerón J, Ferreccio C, et al. Nuevos paradigmas y desafíos en la prevención y control del cáncer de cuello uterino en América Latina. Salud Publica Mex 201052544–59.Spanish 10.1590/S0036-36342010000600010 [DOI] [PubMed] [Google Scholar]
  • 34.Consejo de Salud Suramericano. Resolución 04/2011: Red de Institutos Nacionales de Cáncer de UNASUR (RINC/UNASUR) [Resolution 04/2011: Network of National Cancer Institutes of UNASUR (RINC/UNASUR)]. Rio de Janeiro: Unión de Naciones Suramericanas; 2011. Spanish. Available from: http://www2.rinc-unasur.org/wps/wcm/connect/RINC/site/home [accessed 19 June 2013].
  • 35.Knaul FM, Bustreo F, Ha E, Langer A. Breast cancer: why link early detection to reproductive health interventions in developing countries? Salud Publica Mex. 2009;51(Suppl 2):s220–7. doi: 10.1590/S0036-36342009000800012. [DOI] [PubMed] [Google Scholar]
  • 36.Knaul FM, Bhadelia A, Gralow J, Arreola-Ornelas H, Langer A, Frenk J. Meeting the emerging challenge of breast and cervical cancer in low- and middle-income countries. Int J Gynaecol Obstet. 2012;119(Suppl 1):S85–8. doi: 10.1016/j.ijgo.2012.03.024. [DOI] [PubMed] [Google Scholar]

Articles from Bulletin of the World Health Organization are provided here courtesy of World Health Organization

RESOURCES